Overview

Price chart · mood · technical indicators

LLY

Eli Lilly and Companystock Healthcare

Drug Manufacturers - General

$967.7924.86%Current Market Mood:Bullish

Market Mood

Price Range (1Y)

$623.78$1,133.95

Current: $967.79

Idea: EMA

1Y Return

+13.8%

Sharpe 3Y

1.14

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

LLY

+24.86%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio38.13Forward 25.71

EPS (TTM)$22.9251.4% YoY

Profit margin31.7%HEALTHCARE

Market cap$780.79BMega cap

Wall Street coverage

$1,202.34median target· current $766.68 (+56.8%)31 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 25.71
PEG ratio: 1.28
P/B: 29.23
P/S (TTM): 11.98
EV/EBITDA: 25.59

Profitability & growth

ROE (TTM): 101.2%
Operating margin: 44.9%
Revenue growth YoY: 42.6%
Dividend yield: 0.7%
Beta: 0.50

Last earnings

Apr 30, 2026 · Estimate $7.25 · Reported $8.55

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Eli Lilly and Company

Company profile

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE
Country: USA
Currency: USD

Company profile

HQ: LILLY CORPORATE CENTER, INDIANAPOLIS, IN
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$780.79B

Shares outstanding$893.4M

52W high$1,132.06

52W low$620.46

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

LLY

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Aptar Injectable Sales Soar Amid Pharmaceutical Production Boom

5 Best Healthcare AI Stocks to Buy According to Analysts

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

Sanofi SA Stock (SNY) Moved Down by 5.57% on May 4: What Investors Need To Know

Reddit Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

New heart failure data on BridgeBio drug lands late-breaking ESC slot

France fines Novo Nordisk and Eli Lilly over ads for anti-obesity drugs

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Does Frontdoor Stock Qualify as a Tier-1 Capital Compounder?

Eli Lilly and Company 2026 Q1 - Results - Earnings Call Presentation (NYSE:LLY) 2026-05-03

Pfizer Scores an FDA Approval and a Patent Win in One Week. Here’s What the Stock Could Return by 2028

Johnson & Johnson becomes the latest pharmaceutical company to sign on to TrumpRx

US Bancorp DE Has $11.42 Million Position in Novo Nordisk A/S $NVO

Hussman Strategic Advisors Inc. Acquires Shares of 8,400 Amgen Inc. $AMGN

Narwhal Capital Management Sells 2,288 Shares of Eli Lilly and Company $LLY

Keybank National Association OH Sells 4,443 Shares of Eli Lilly and Company $LLY

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Analysts

GC Wealth Management RIA LLC Sells 6,653 Shares of Eli Lilly and Company $LLY

About Eli Lilly and Company

Classification

Company profile

LLY

Market Comparison

LLY Market Analysis

Overview

LLY

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Aptar Injectable Sales Soar Amid Pharmaceutical Production Boom

5 Best Healthcare AI Stocks to Buy According to Analysts

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

Sanofi SA Stock (SNY) Moved Down by 5.57% on May 4: What Investors Need To Know

Reddit Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

New heart failure data on BridgeBio drug lands late-breaking ESC slot

France fines Novo Nordisk and Eli Lilly over ads for anti-obesity drugs

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Does Frontdoor Stock Qualify as a Tier-1 Capital Compounder?

Eli Lilly and Company 2026 Q1 - Results - Earnings Call Presentation (NYSE:LLY) 2026-05-03

Pfizer Scores an FDA Approval and a Patent Win in One Week. Here’s What the Stock Could Return by 2028

Johnson & Johnson becomes the latest pharmaceutical company to sign on to TrumpRx

US Bancorp DE Has $11.42 Million Position in Novo Nordisk A/S $NVO

Hussman Strategic Advisors Inc. Acquires Shares of 8,400 Amgen Inc. $AMGN

Narwhal Capital Management Sells 2,288 Shares of Eli Lilly and Company $LLY

Keybank National Association OH Sells 4,443 Shares of Eli Lilly and Company $LLY

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Analysts

GC Wealth Management RIA LLC Sells 6,653 Shares of Eli Lilly and Company $LLY

About Eli Lilly and Company

Classification

Company profile

LLY

Market Comparison